LDL Reduction in ESRD Patients

Expected LDL Reduction with Rosuvastatin

• Rosuvastatin 10mg is classified as a moderate-intensity statin therapy with an expected LDL-C reduction of 30-49% when used as monotherapy 1

Use of PCSK9 Inhibitors in ESRD

• PCSK9 inhibitors can be used in patients with ESRD who require additional LDL-C lowering beyond what is achieved with statin and ezetimibe therapy 2, 3
• PCSK9 inhibitors are powerful LDL-lowering drugs that reduce LDL-C by 40-65% and have strong evidence for cardiovascular risk reduction when added to statin therapy 3
• The American College of Cardiology guidelines do not contraindicate the use of PCSK9 inhibitors in ESRD patients 4, 5
• For patients with ASCVD on maintenance hemodialysis, decisions about the use of PCSK9 inhibitors should be individualized based on the potential net clinical benefit in the context of the patient's projected longevity and comorbidities 5

Treatment Algorithm for ESRD Patients

• Start with ezetimibe 10mg daily, then add rosuvastatin 10mg daily (expected additional 30-40% LDL-C reduction) 1, 2
• If LDL-C goal is not achieved and additional reduction is needed, consider adding a PCSK9 inhibitor (evolocumab or alirocumab) 2, 3

Important Considerations and Potential Pitfalls

• Statin intolerance is frequent in clinical practice, with muscle-related symptoms being the most common adverse effect; monitor for these symptoms when initiating rosuvastatin 1
• For patients who cannot tolerate high-intensity statins, moderate-intensity statin plus ezetimibe is still effective for LDL-C reduction 6
• PCSK9 inhibitors are more expensive than other lipid-lowering therapies, which may limit accessibility, so consider cost and insurance coverage when recommending them 3